AIM/HYPOTHESIS: The experimental aim of this study was to determine whether ET-1-mediated vasoconstrictor tone is elevated in adult humans with impaired fasting blood glucose concentrations, independent of other cardiovascular risk factors. METHODS: Forearm blood flow (FBF: plethysmography) responses to intra-arterial infusion of selective ETA receptor blockade (BQ-123: 100 nmol/min for 60 min) and non-selective ETA/B blockade (BQ-123 + BQ-788: 50 nmol/min for 60 min) were determined in 28 middle-aged, sedentary adults (17 M/11 F): 14 with normal fasting blood glucose (age: 57 ± 2 yr; 6 F/8 M; BMI: 29.2 ± 0.9 kg/m(2); glucose: 4.9 ± 0.1 mmol/L) and 14 impaired fasting blood glucose (58 ± 1 yr; 5 F/9 M; 29.6 ± 1.1 kg/m(2); 5.8 ± 0.1 mmol/L) concentrations. RESULTS: Selective ETA receptor blockade elicited a significantly greater (∼20%) increase in FBF in the impaired fasting glucose adults compared with the normoglycemia controls. ETA/B blockade resulted in a further 2-fold increase (P < 0.05) in FBF above that elicited by ETA receptor antagonism in the impaired fasting glucose but not normal fasting glucose adults. There was a positive correlation between fasting blood glucose levels and the peak vascular responses to ETA (r = 0.44; P < 0.05) and ETA/B (r = 0.62; P < 0.05) blockade. No other anthropometric, hemodynamic or metabolic variable was correlated with the blood flow responses to ET-1 receptor blockade. CONCLUSIONS/ INTERPRETATION: ET-1-mediated vasoconstrictor tone is elevated in adults with impaired fasting blood glucose concentrations, independent of other cardiometabolic risk factors. Enhanced ET-1 system activity may underlie endothelial vasomotor dysfunction and increased cardiovascular risk in adults with impaired fasting blood glucose concentrations.
AIM/HYPOTHESIS: The experimental aim of this study was to determine whether ET-1-mediated vasoconstrictor tone is elevated in adult humans with impaired fasting blood glucose concentrations, independent of other cardiovascular risk factors. METHODS: Forearm blood flow (FBF: plethysmography) responses to intra-arterial infusion of selective ETA receptor blockade (BQ-123: 100 nmol/min for 60 min) and non-selective ETA/B blockade (BQ-123 + BQ-788: 50 nmol/min for 60 min) were determined in 28 middle-aged, sedentary adults (17 M/11 F): 14 with normal fasting blood glucose (age: 57 ± 2 yr; 6 F/8 M; BMI: 29.2 ± 0.9 kg/m(2); glucose: 4.9 ± 0.1 mmol/L) and 14 impaired fasting blood glucose (58 ± 1 yr; 5 F/9 M; 29.6 ± 1.1 kg/m(2); 5.8 ± 0.1 mmol/L) concentrations. RESULTS: Selective ETA receptor blockade elicited a significantly greater (∼20%) increase in FBF in the impaired fasting glucose adults compared with the normoglycemia controls. ETA/B blockade resulted in a further 2-fold increase (P < 0.05) in FBF above that elicited by ETA receptor antagonism in the impaired fasting glucose but not normal fasting glucose adults. There was a positive correlation between fasting blood glucose levels and the peak vascular responses to ETA (r = 0.44; P < 0.05) and ETA/B (r = 0.62; P < 0.05) blockade. No other anthropometric, hemodynamic or metabolic variable was correlated with the blood flow responses to ET-1 receptor blockade. CONCLUSIONS/ INTERPRETATION:ET-1-mediated vasoconstrictor tone is elevated in adults with impaired fasting blood glucose concentrations, independent of other cardiometabolic risk factors. Enhanced ET-1 system activity may underlie endothelial vasomotor dysfunction and increased cardiovascular risk in adults with impaired fasting blood glucose concentrations.
Authors: O F Wagner; G Christ; J Wojta; H Vierhapper; S Parzer; P J Nowotny; B Schneider; W Waldhäusl; B R Binder Journal: J Biol Chem Date: 1992-08-15 Impact factor: 5.157
Authors: Allison E DeVan; Iratxe Eskurza; Gary L Pierce; Ashley E Walker; Kristen L Jablonski; Rachelle E Kaplon; Douglas R Seals Journal: Clin Sci (Lond) Date: 2013-03 Impact factor: 6.124
Authors: J N Patel; A Jager; C Schalkwijk; R Corder; J A Douthwaite; J S Yudkin; S W Coppack; C D A Stehouwer Journal: Clin Sci (Lond) Date: 2002-10 Impact factor: 6.124
Authors: J G Raimann; B Canaud; M Etter; J P Kooman; N W Levin; D Marcelli; C Marelli; A Power; N Duncan; F M van der Sande; P Carioni; S Thijssen; X Xu; L A Usvyat; Y Wang; P Kotanko Journal: J Hum Hypertens Date: 2015-07-30 Impact factor: 3.012
Authors: Natalia G Rocha; Danielle L Templeton; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza Journal: Metabolism Date: 2014-04-18 Impact factor: 8.694
Authors: Tyler D Bammert; Jamie G Hijmans; Whitney R Reiakvam; Ma'ayan V Levy; Lillian M Brewster; Zoe A Goldthwaite; Jared J Greiner; Kelly A Stockelman; Christopher A DeSouza Journal: Biochem Biophys Res Commun Date: 2017-09-20 Impact factor: 3.575
Authors: L-A Khuu; F Tayyari; J M Sivak; J G Flanagan; S Singer; M H Brent; D Huang; O Tan; C Hudson Journal: Eye (Lond) Date: 2017-05-26 Impact factor: 3.775